Sodium valproate in tardive dyskinesia

Daniel Casey, John Hammerstad

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recent findings suggest that tardive dyskinesia may involve GABA-ergic influences in addition to dopaminergic receptor hypersensitivity and relative cholinergic hypofunction. Sodium valproate, which may increase brain GABA, moderately reduced tardive dyskinesia with doses of 900-3000 mg/day, as measured by a tremor-graph and rating scales. There was no correlation between dosage, blood levels, or clinical response. Although the symptoms were not completely controlled, valproate and other GABA-ergic agents may be useful compounds in studying and treating tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)483-485
Number of pages3
JournalJournal of Clinical Psychiatry
Volume40
Issue number11
StatePublished - 1979
Externally publishedYes

Fingerprint

Valproic Acid
gamma-Aminobutyric Acid
GABA Agents
Tremor
Cholinergic Agents
Hypersensitivity
Brain
Tardive Dyskinesia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Sodium valproate in tardive dyskinesia. / Casey, Daniel; Hammerstad, John.

In: Journal of Clinical Psychiatry, Vol. 40, No. 11, 1979, p. 483-485.

Research output: Contribution to journalArticle

Casey, Daniel ; Hammerstad, John. / Sodium valproate in tardive dyskinesia. In: Journal of Clinical Psychiatry. 1979 ; Vol. 40, No. 11. pp. 483-485.
@article{9d6a992d903749c4b96ba19eae084e2e,
title = "Sodium valproate in tardive dyskinesia",
abstract = "Recent findings suggest that tardive dyskinesia may involve GABA-ergic influences in addition to dopaminergic receptor hypersensitivity and relative cholinergic hypofunction. Sodium valproate, which may increase brain GABA, moderately reduced tardive dyskinesia with doses of 900-3000 mg/day, as measured by a tremor-graph and rating scales. There was no correlation between dosage, blood levels, or clinical response. Although the symptoms were not completely controlled, valproate and other GABA-ergic agents may be useful compounds in studying and treating tardive dyskinesia.",
author = "Daniel Casey and John Hammerstad",
year = "1979",
language = "English (US)",
volume = "40",
pages = "483--485",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - Sodium valproate in tardive dyskinesia

AU - Casey, Daniel

AU - Hammerstad, John

PY - 1979

Y1 - 1979

N2 - Recent findings suggest that tardive dyskinesia may involve GABA-ergic influences in addition to dopaminergic receptor hypersensitivity and relative cholinergic hypofunction. Sodium valproate, which may increase brain GABA, moderately reduced tardive dyskinesia with doses of 900-3000 mg/day, as measured by a tremor-graph and rating scales. There was no correlation between dosage, blood levels, or clinical response. Although the symptoms were not completely controlled, valproate and other GABA-ergic agents may be useful compounds in studying and treating tardive dyskinesia.

AB - Recent findings suggest that tardive dyskinesia may involve GABA-ergic influences in addition to dopaminergic receptor hypersensitivity and relative cholinergic hypofunction. Sodium valproate, which may increase brain GABA, moderately reduced tardive dyskinesia with doses of 900-3000 mg/day, as measured by a tremor-graph and rating scales. There was no correlation between dosage, blood levels, or clinical response. Although the symptoms were not completely controlled, valproate and other GABA-ergic agents may be useful compounds in studying and treating tardive dyskinesia.

UR - http://www.scopus.com/inward/record.url?scp=0018566958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018566958&partnerID=8YFLogxK

M3 - Article

C2 - 385585

AN - SCOPUS:0018566958

VL - 40

SP - 483

EP - 485

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -